2021 American Transplant Congress
Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients
Transplant Institute, Loma Linda University Health, San Bernardino, CA
*Purpose: We report our experience on virologic and graft outcomes of HCV-negative patients transplanted with HCV NAT+ (viremic) and HCV Ab+/NAT- (non-viremic) livers and kidneys…2021 American Transplant Congress
Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors
UVA Health System, University of Virginia, Charlottesville, VA
*Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…2021 American Transplant Congress
Association of Donor Hepatitis C Virus Infection Status and Risk of Bk Polyomavirus Viremia After Kidney Transplantation
*Purpose: Transplantation of kidneys from deceased donors with hepatitis C virus (HCV) infection into HCV-negative recipients has become more common, but some studies have suggested…2021 American Transplant Congress
Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients
University of North Carolina Medical Center, Chapel Hill, NC
*Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY
*Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Are Tacrolimus Concentrations Reduced with Direct-acting Antiviral Administration in Transplant Recipients?
Pharmacy, Penn State Health Hershey Medical Center, Hershey, PA
*Purpose: To evaluate the effects of direct-acting antivirals (DAAs) on tacrolimus trough concentrations and clinical outcome and to assess the need for a priori dose…2021 American Transplant Congress
Outcomes of Kidney Transplantation from Hepatitis C Virus (HCV) Infected Donors Stratified by Recipient HCV Serostatus: A Mate Kidney Analysis
*Purpose: Kidneys from donors infected with hepatitis C virus (HCV) are increasingly used for transplantation into HCV positive (+) recipients historically and into HCV negative…2021 American Transplant Congress
Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 28
- Next Page »